Expiration date: 01/2025

Available on request

Action:

antineoplastic

Composition:

of nintedanib 100 or 150mg econsultant. V. in-VA: triglyceride with chains of medium size - 161.1 mg, hard fat - 76.5 mg, lecithin - 1.8 mg.

Indications:

Locally advanced, metastatic or recurrent non-small cell lung cancer (adenocarcinoma) after first-line chemotherapy in combination with docetaxel, idiopathic pulmonary fibrosis (idiopathic fibrotic alveolitis)

to treat and slow the progression of the disease